11/01/2025 19:32:23
04/04/2023 17:00:00
04/04/2023 18:00:00
Participate in this live event
Register with your My PCR account, add it to your calendar and receive automatic reminders.
Please log into your MyPCR account before proceeding
Co-Chairpersons:
Speakers:
Objectives:
Join this webinar if you want to:
- Learn about the latest randomised results on the treatment of tricuspid regurgitation
- Understand how these results may impact on daily clinical practice
- Identify remaining gaps in knowledge and future research areas
Introducing the PCR Tricuspid Focus Group
The Focus Group is committed to fostering the establishment of tricuspid therapies, improving outcomes, and delivering sustainable clinical solutions for complex patients. Discover an overview of the new initiative’s mission and five ongoing working groups dedicated to improving the treatment of patients with tricuspid valve disease
This webinar is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of External CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
With F. Praz, F. Maisano, V. Delgado, R. Hahn, M. Metra and P. Sorajja
Thank you for watching the webinar
To download your certificate of attendance and get your CME credits, please complete the quick satisfaction survey now!
Access here
Co-Chairpersons:
Speakers:
Objectives:
Watch the replay of this webinar if you want to:
- Learn about the latest randomised results on the treatment of tricuspid regurgitation
- Understand how these results may impact on daily clinical practice
- Identify remaining gaps in knowledge and future research areas
Introducing the PCR Tricuspid Focus Group
The Focus Group is committed to fostering the establishment of tricuspid therapies, improving outcomes, and delivering sustainable clinical solutions for complex patients. Discover an overview of the new initiative’s mission and five ongoing working groups dedicated to improving the treatment of patients with tricuspid valve disease